Tenax Therapeutics, Inc - Volume dana dhuwit perusahaan TENX

Lambang korporat lan logo Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics is developing cardiology drugs under strict FDA supervision and robust patent protection. The current cash balance demonstrates financial stability, while 0.12 represents the latest level value. Business revenues rely on insurance fund procurement, and the research-oriented management is successfully adapting Phase III trial protocols for the key product.

Tenax Therapeutics Inc - Volume dana dhuwit perusahaan TENX (periode 04.07.2022 - 21.11.2026)

Rincian analitis lan laporan data perusahaan Tenax Therapeutics, Inc. (TENX)

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:TENX tenaxthera.com
Produk merek tenaxthera.com

This indicator assesses solvency and default risk by tracking the volume of liquid assets available to cover current liabilities. The cash balance trend for Tenax Therapeutics (TENX) on the GURU.Markets platform reflects the burn rate of reserves, which is critical for Tenax Therapeutics, where Christopher Kenyon's scientific discipline ensures that funding strictly aligns with the clinical trial schedule for pulmonary hypertension drugs.